AGIOS PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Other Comprehensive Income (Loss), Net of Tax of -$4.58 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2022-11-03
- AGIOS PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2022-09-30 was -$4.58M.
- AGIOS PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2022-06-30 was -$2.76M.
- AGIOS PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2022-03-31 was -$6.55M.
- AGIOS PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2021-09-30 was -$54.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month |
|---|---|---|---|
| 2022-09-30 | -$4.58M 10-Q · filed 2022-11-03 | -$7.34M derived: sum of 2 quarters · filed 2022-11-03 | -$13.88M derived: sum of 3 quarters · filed 2022-11-03 |
| 2022-06-30 | -$2.76M 10-Q · filed 2022-11-03 | -$9.30M derived: sum of 2 quarters · filed 2022-11-03 | |
| 2022-03-31 | -$6.55M 10-Q · filed 2022-11-03 | ||
| 2021-09-30 | -$54.00K 10-Q · filed 2022-11-03 | -$195.00K derived: sum of 2 quarters · filed 2022-11-03 | -$303.00K derived: sum of 3 quarters · filed 2022-11-03 |
| 2021-06-30 | -$141.00K 10-Q · filed 2022-11-03 | -$249.00K derived: sum of 2 quarters · filed 2022-11-03 | |
| 2021-03-31 | -$108.00K 10-Q · filed 2022-11-03 | ||
| 2020-09-30 | -$973.00K 10-Q · filed 2021-11-03 | $589.00K derived: sum of 2 quarters · filed 2021-11-03 | $461.00K derived: sum of 3 quarters · filed 2021-11-03 |
| 2020-06-30 | $1.56M 10-Q · filed 2021-11-03 | $1.43M derived: sum of 2 quarters · filed 2021-11-03 | |
| 2020-03-31 | -$128.00K 10-Q · filed 2021-11-03 | ||
| 2019-09-30 | -$26.00K 10-Q · filed 2020-11-05 | $948.00K derived: sum of 2 quarters · filed 2020-11-05 | $2.63M derived: sum of 3 quarters · filed 2020-11-05 |
| 2019-06-30 | $974.00K 10-Q · filed 2020-11-05 | $2.66M derived: sum of 2 quarters · filed 2020-11-05 | |
| 2019-03-31 | $1.69M 10-Q · filed 2020-11-05 | ||
| 2018-09-30 | $279.00K 10-Q · filed 2019-10-31 | $524.00K derived: sum of 2 quarters · filed 2019-10-31 | -$730.00K derived: sum of 3 quarters · filed 2019-10-31 |
| 2018-06-30 | $245.00K 10-Q · filed 2019-10-31 | -$1.01M derived: sum of 2 quarters · filed 2019-10-31 | |
| 2018-03-31 | -$1.25M 10-Q · filed 2019-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |